Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) Income from Non-Controlling Interests (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Income from Non-Controlling Interests for 5 consecutive years, with -$8000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Income from Non-Controlling Interests fell 60.0% year-over-year to -$8000.0, compared with a TTM value of -$71000.0 through Sep 2025, down 57.78%, and an annual FY2024 reading of -$105000.0, down 5.0% over the prior year.
  • Income from Non-Controlling Interests was -$8000.0 for Q3 2025 at Barinthus Biotherapeutics, down from $5000.0 in the prior quarter.
  • Across five years, Income from Non-Controlling Interests topped out at $5000.0 in Q2 2025 and bottomed at -$118000.0 in Q1 2021.
  • Average Income from Non-Controlling Interests over 4 years is -$30384.6, with a median of -$15000.0 recorded in 2024.
  • The sharpest move saw Income from Non-Controlling Interests crashed 2133.33% in 2024, then skyrocketed 133.33% in 2025.
  • Year by year, Income from Non-Controlling Interests stood at -$58000.0 in 2021, then soared by 105.17% to $3000.0 in 2023, then plummeted by 2133.33% to -$61000.0 in 2024, then soared by 86.89% to -$8000.0 in 2025.
  • Business Quant data shows Income from Non-Controlling Interests for BRNS at -$8000.0 in Q3 2025, $5000.0 in Q2 2025, and -$7000.0 in Q1 2025.